14 results about "Atrial flutter" patented technology

The invention provides an atrial fibrillation postoperative recurrence prediction method fusing electrocardiosignals and clinical characteristics. The method comprises the following steps: acquiring data of a patient before an ablation operation, and carrying out resampling, denoising and normalization preprocessing and data segment segmentation on an electrocardiosignal; extracting spatio-temporal features by using a deep network containing a residual convolutional block and a long and short term memory module; screening high-discrimination clinical baseline features through statistical analysis and a machine learning model; extracting time-frequency domain and nonlinear features of short-time heart rate variability; designing a cross-modal attention fusion module to carry out feature adaptive weighted fusion; and outputting a recurrence probability through a multi-layer perceptron based on the fusion features. The method improves the prediction precision through feature complementarity, facilitates the recognition of high-recurrence-risk patients, is suitable for sinus heart rhythm signals or atrial flutter and atrial fibrillation signals, and has a certain application value in the field of cardiovascular precision medical treatment. The method can be popularized to all prediction researches based on the electrophysiological signals.

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

The present disclosure relates to compositions and methods, including prodrugs of (S)-sec-butyl 2-(3-(4-(2- (diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, ventricular arrhythmias, or ventricular fibrillation.

The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation / atrial flutter and / or ventricular arrhythmias.

A photoplethysmography or PPG signal processing device configured to detect atrial flutter, includes a processor and memory including computer program code The processor and memory are configured to cause the PPG signal processing device toobtain (101) at least one PPG signal (200) for a human or animal;detect (102) heartbeats (201, 202, 203, 204, 205, . . . ) in the at least one PPG signal (200); anddetermine (103) interbeat intervals (301, 302, 303, 304, . . . ) for pairs of consecutive heartbeats (201-202, 202-203, 203-204, 204-205, . . . ) in the at least one PPG signal (200).The processor and memory cause the PPG signal processing device to detect (104) interbeat interval baselines, each interbeat interval baseline (302-304) corresponding to a plurality of consecutive interbeat intervals (302, 303, 304) that are constant within a predefined tolerance value;determine (105) respective average interbeat interval values (401, 402, . . . ) for the interbeat interval baselines (302-304); anddetect (110) a relationship between the average interbeat interval values (401, 402, . . . ; 501, 502, . . . ).

A method of treating arrhythmia in a human subject with orally administered sulcardine, or a pharmaceutically acceptable salt thereof, is provided. The arrhythmia may be atrial fibrillation or atrial flutter. The method, which comprises administering a sulcardine-containing composition to a human subject, may produce in a human subject pan-ECG parameter changes comprising an increase in QTcF or a decrease in JTp.

The present invention involves novel safe dosage regimens comprising the administration of a loading and maintenance dose of dofetilide iv, followed by oral dosing of dofetilide. Methods include (a) reducing the risk of developing atrial fibrillation (AF) and / or atrial flutter (AFL) post coronary bypass surgery (CABS); (b) terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing; and, (c) converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL.

The invention relates to an atrial arrhythmia recognition method and system based on a space-time diagram neural network and atrial signal source reconstruction and a storage medium. According to the method, source decoupling of ventricular and atrial activities is achieved through a signal processing architecture combining independent component analysis and variational mode decomposition; the atrial signal extraction distortion under wide QRS wave group and noise interference is fundamentally avoided; meanwhile, a multi-modal feature system fusing time domain dynamics, frequency domain morphology and spatial synchronism is constructed, and a space-time diagram convolutional network constructed based on lead physical and physiological topology is matched, so that the space-time dependency relationship of the multi-lead electrocardiosignals is effectively captured. In addition, the introduced attention mechanism provides a visual decision basis, and the accuracy and interpretability of atrial fibrillation and atrial flutter identification in complex pathological scenes with conduction block and the like are remarkably improved.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.

The present invention relates to a safe dosage regimen comprising administering a dose of dofelilide IV followed by oral administration of dofelilide. In a first aspect, the present invention relates to a method of reducing the risk of atrial fibrillation (AF) and / or atrial flutter (AFL) following coronary artery bypass surgery (CABS) by intravenously administering a loaded dose and a sustaining dose of dofililide followed by an oral dose. In a second aspect, the present invention relates to a method of terminating an arrhythmic storm in a patient after implementation of an implantable defibrillator by loading and maintaining infusion and then oral administration of doferide intravenously. In a third aspect, the present invention also relates to a method of transforming atrial fibrillation (AF) or atrial flutter (AFL) in a patient suffering from highly symptomatic AF or AFL by intravenous administration of at least a loading dose of dofililide, or if it fails, cardioversion and maintenance of infusion, followed by long term oral administration.